Acumen Pharmaceuticals, Inc. Operating Leases, Rent Expense
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Leases, Rent Expense of $27.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2023-03-27
- Acumen Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2022-09-30 was $27.00K, a 32.50% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2022-06-30 was $27.00K, a 32.50% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2022-03-31 was $27.00K, a 0.00% change year-over-year.
- Acumen Pharmaceuticals, Inc. operating leases, rent expense for the quarter ending 2021-12-31 was $40.00K.
- Acumen Pharmaceuticals, Inc. operating leases, rent expense for fiscal 2021 was $147.00K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $27.00K 10-Q · filed 2022-11-14 | $54.00K derived: sum of 2 quarters · filed 2022-11-14 | $81.00K 10-Q · filed 2022-11-14 | $121.00K derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-06-30 | $27.00K 10-Q · filed 2022-08-15 | $54.00K 10-Q · filed 2022-08-15 | $94.00K derived: sum of 3 quarters · filed 2023-03-27 | $134.00K derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-03-31 | $27.00K 10-Q · filed 2022-05-16 | $67.00K derived: sum of 2 quarters · filed 2023-03-27 | $107.00K derived: sum of 3 quarters · filed 2023-03-27 | $147.00K derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $80.00K derived: sum of 2 quarters · filed 2023-03-27 | $120.00K derived: sum of 3 quarters · filed 2023-03-27 | $147.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $40.00K 10-Q · filed 2022-11-14 | $80.00K derived: sum of 2 quarters · filed 2022-11-14 | $107.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $40.00K 10-Q · filed 2022-08-15 | $67.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $27.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |